Close menu

November 25th, 2021 | 11:46 CET

BB Biotech, Sativa Wellness, Carnival: Anti-aging as a megatrend

  • Health
Photo credits:

Anti-aging medicine is one of the most exciting research topics of our time. Already in 2018, Citigroup named the field as one of the ten rising topics of the future. While the pandemic has obscured many long-term ventures in the media, the work continues. People have long been optimizing and working to feel at least a little younger. We present three stocks related to biotechnology, anti-aging and wellness.

time to read: 3 minutes | Author: Nico Popp
ISIN: BB BIOTECH NAM. SF 0_20 | CH0038389992 , SATIVA WELLNESS GROUP INC | CA80403E1043 , CARNIVAL PLC DL 1_66 | GB0031215220

Table of contents:

    BB Biotech: This stock is exciting and dull at the same time

    At first glance, BB Biotech is not an anti-aging stock. However, the Swiss investment company with a great deal of know-how around biotechnology and medicine has several companies in its portfolio researching the greatest challenges of our time. These include diseases such as cancer and Alzheimer's. Indirectly, this can also be called anti-aging - after all, the quality of life increases in old age when the typical infirmities eventually disappear. Since the work on new drugs is lengthy, challenging and difficult to plan, BB Biotech's investment structure offers a perfect vehicle for investors who do not want to put all their eggs in one basket and who want to rely on independent expertise in a highly complex area such as biotechnology.

    Since BB Biotech has been active in this field for many years and has filled key positions in the Company with specialists from the fields of medicine and science, an investment in the Company is akin to an accolade for biotech companies. Investors can thus assume that there is at least a good perspective for the respective project. In addition, there is the diversification effect - with BB Biotech, investors do not put all their eggs in one basket. However, a negative factor is that the current value of the investments, which are generally not listed on the stock exchange themselves, is not very transparent. It can sometimes take some time before the market recognizes the potential and also prices in BB Biotech. The share has only gained just under 15% over the past year, making it a rather conservative stock. The dividend yield, however, is a proud 5%.

    Sativa Wellness: Self-tests and telemedicine with potential

    There is no dividend at Sativa Wellness - but a payout is probably the last thing investors expect from the wellness stock: it is all about growth. Just recently, the Company announced a distribution partnership for blood tests. The offer is aimed gender-specifically at open-minded customers who want to optimize their health. These include analysis around hormone levels and fertility, pre-diabetes and cholesterol, and general organ health and micronutrient supply. As the partnership allows customers to have blood drawn when needed effortlessly, this lowers the hurdle and could drive sales of the blood tests. Fitness enthusiasts and anti-aging supporters, in particular, attach great importance to preventive healthcare and a healthy lifestyle. A laboratory result indicates potential or reassures. The target group is happy to pay for this.

    In addition to the blood test business, Sativa Wellness also offers high-quality CBD products and laboratory services related to cannabis diagnostics. In the first half of the year, the Company achieved positive cash flow and gained further tailwind against the backdrop of increasing liberalization and legalization around cannabis. The Company's laboratory analysis and telemedicine offerings are also likely to be growth areas given the high awareness of personal healthcare. The share has been running sideways for months. Good figures could kiss the value awake. Given the low market capitalization of only around EUR 14 million, the stock has a lot going for it in terms of dynamic development.

    Carnival: This share has fallen out of the times

    The cruise operator Carnival also stands for wellness: spacious pools, good food, a little sport on deck - all this speaks for relaxation and well-being. Nevertheless, the offer seems a little out of date. Most people under 60 are more likely to associate Carnival with fine dust, crowds of tourists storming Venice, and petty squabbles at the buffet. In the wake of the Corona pandemic, the stock has dropped significantly and was always considered a comeback candidate. Although the share has already recovered over the past year, it is still trading about 66% below where it was three years ago. Whether the share will reach the prices of that time again is questionable. The world after Corona will be a different one - perhaps that is just as well.

    Nevertheless, those who believe in Carnival's potential can make a note of the stock for a comeback. BB Biotech, on the other hand, is more of a "leave it" stock. Here, a solid dividend and a lot of fantasy beckon, even if it does not look like it at first glance. The best perspective for speculative investors is Sativa Wellness. The Company operates in exciting areas and has recently presented increasingly better figures. If the market recognizes this and there are no setbacks, the value could become promising.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST

    Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

    • Biotechnology
    • Covid19
    • Health

    Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...


    Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET

    CureVac, Cardiol Therapeutics, Bayer - roaring profits!

    • Health

    The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.


    Commented by Nico Popp on February 8th, 2021 | 07:30 CET

    Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

    • Health

    Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.